CN115025216A - 一种用于癌症治疗的组合物和方法 - Google Patents
一种用于癌症治疗的组合物和方法 Download PDFInfo
- Publication number
- CN115025216A CN115025216A CN202210500469.6A CN202210500469A CN115025216A CN 115025216 A CN115025216 A CN 115025216A CN 202210500469 A CN202210500469 A CN 202210500469A CN 115025216 A CN115025216 A CN 115025216A
- Authority
- CN
- China
- Prior art keywords
- h2afx
- cbx3
- composition
- monoclonal antibody
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
基因名称 | 引物序列 |
H2AFX | F 5’-gaggctttggtgggagagac-3’;R 5’-agttcagaagccaacggagg-3’ |
CBX3 | F 5’-gccgcgaacgtaatagctct-3’;R 5’-gcaccaagtctgcctcatct-3’ |
β-actin | F 5’-tcctccctggagaagagcta-3’;R 5’-gtacttgcgctcaggaggag-3’ |
名称 | siRNA序列 |
si-H2AFX | F 5’-aaauuaguccaucuaaaacuc-3’;R 5’-guuuuagauggacuaauuuua-3’ |
si-CBX3 | F 5’-uuauugcagacuugaagagcu-3’;R 5’-cucuucaagucugcaauaaaa-3’ |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210500469.6A CN115025216B (zh) | 2022-05-10 | 2022-05-10 | 一种用于癌症治疗的组合物和方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210500469.6A CN115025216B (zh) | 2022-05-10 | 2022-05-10 | 一种用于癌症治疗的组合物和方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115025216A true CN115025216A (zh) | 2022-09-09 |
CN115025216B CN115025216B (zh) | 2023-08-11 |
Family
ID=83119584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210500469.6A Active CN115025216B (zh) | 2022-05-10 | 2022-05-10 | 一种用于癌症治疗的组合物和方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115025216B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106729756A (zh) * | 2017-02-28 | 2017-05-31 | 北京泱深生物信息技术有限公司 | 生物标志物作为靶标在肺腺癌诊治中的应用 |
CN111254146A (zh) * | 2020-03-13 | 2020-06-09 | 青岛市中心医院 | Linc01331基因抑制剂在制备治疗肺癌药物中的用途 |
CN111378753A (zh) * | 2020-04-01 | 2020-07-07 | 天津医科大学肿瘤医院 | 人pno1基因在肺癌中的用途及相关产品 |
US20210292755A1 (en) * | 2016-10-27 | 2021-09-23 | Selexel | Novel double-stranded oligonucleotides for the treatment of cancer |
-
2022
- 2022-05-10 CN CN202210500469.6A patent/CN115025216B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210292755A1 (en) * | 2016-10-27 | 2021-09-23 | Selexel | Novel double-stranded oligonucleotides for the treatment of cancer |
CN106729756A (zh) * | 2017-02-28 | 2017-05-31 | 北京泱深生物信息技术有限公司 | 生物标志物作为靶标在肺腺癌诊治中的应用 |
CN111254146A (zh) * | 2020-03-13 | 2020-06-09 | 青岛市中心医院 | Linc01331基因抑制剂在制备治疗肺癌药物中的用途 |
CN111378753A (zh) * | 2020-04-01 | 2020-07-07 | 天津医科大学肿瘤医院 | 人pno1基因在肺癌中的用途及相关产品 |
Non-Patent Citations (2)
Title |
---|
侯清华等: "CBX3在肺腺癌中的表达、预后相关性及对癌细胞生物学行为的影响", 《中国癌症杂志》 * |
曹灵杰等: "H2AFX基因在肺腺癌中的表达及对预后的影响", 《华西医学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN115025216B (zh) | 2023-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111073979B (zh) | 阻断ccl28趋化通路的胃癌治疗方法 | |
Han et al. | Low-expression of TMEM100 is associated with poor prognosis in non-small-cell lung cancer | |
AU2018227146A1 (en) | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate | |
Deng et al. | High expression of the newly found long noncoding RNA Z38 promotes cell proliferation and oncogenic activity in breast cancer | |
US10155808B2 (en) | Monoclonal antibody against human PrPc and use thereof | |
Yuan et al. | Jiedu sangen decoction reverses epithelial-to-mesenchymal transition and inhibits invasion and metastasis of colon cancer via AKT/GSK-3β signaling pathway | |
Wang et al. | Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF‐1 Alpha/VEGF signaling | |
Feng et al. | Effect of solanum lyratum polysaccharide on malignant behaviors of lung cancer cells by regulating the circ_UHRF1/miR-513b-5p axis | |
Wang et al. | Pretreatment with gemcitabine/5‐fluorouracil enhances the cytotoxicity of trastuzumab to HER2‐negative human gallbladder cancer cells in vitro and in vivo | |
CN115025216A (zh) | 一种用于癌症治疗的组合物和方法 | |
US20220403395A1 (en) | Composition for inhibiting growth of cancer stem cells, containing wdr34 inhibitor, and use thereof | |
CN105749283B (zh) | 基于转录因子zeb1在制备促进乳腺癌化疗敏感性的药物中的应用 | |
CN110170051A (zh) | Klf12蛋白在制备治疗非小细胞肺癌药物中的应用 | |
CN113528528B (zh) | 一种促进耐伊马替尼慢性髓细胞白血病细胞K562/G01凋亡shRNA及其应用 | |
Wang et al. | The effects of silencing the Her2 gene on proliferation and angiogenesis of meningioma cells in vivo and in vitro | |
CN110538179B (zh) | Yg1702在制备aldh18a1特异性抑制剂中的应用 | |
CN116474095A (zh) | 小g蛋白rbj的抑制剂的应用 | |
CN111701025A (zh) | 用于治疗肾细胞癌的药物及其应用 | |
KR101921676B1 (ko) | Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법 | |
CN105624275B (zh) | Eif4g1在鳞癌诊断和治疗中的应用 | |
CN117607442B (zh) | 一种预测乳腺癌免疫治疗效果的标志物、试剂盒与应用 | |
KR20200022187A (ko) | Nono의 발현 또는 활성 억제제를 유효성분으로 포함하는 방사선 민감성 증진용 조성물 | |
KR20180129585A (ko) | Mage-1에 특이적으로 결합하는 압타머 및 이의 용도 | |
CN113521291B (zh) | Znf143-mdig-cdc6轴在肝细胞癌中的应用 | |
CN111139299B (zh) | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230614 Address after: 314303 North side of the first floor and second floor of Zhejiang Yumei Technology Co., Ltd., No. 383 Jinhe Road, Qinshan Street Industrial Park, Haiyan County, Jiaxing, Zhejiang Province Applicant after: Zhejiang Yihe Medical Technology Co.,Ltd. Applicant after: Wang Zhirong Address before: 510403 No. 4a023, 4th floor, No. 165 Sanyuanli Avenue, Yuexiu District, Guangzhou, Guangdong Province Applicant before: Guangzhou Lekang Biomedical Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |